RAS-targeted drug daraxonrasib wins FDA and EU approval for metastatic pancreatic cancer
targetedonc.com

RAS-targeted drug daraxonrasib wins FDA and EU approval for metastatic pancreatic cancer

The gist

US and EU regulators approved daraxonrasib for previously treated metastatic pancreatic cancer, with trial data showing median survival of 13.2 vs 6.7 months.
The drug nearly doubled survival over chemotherapy in a disease where half of patients die within three months.

How it unfolded

  1. Aug 26, 2026The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who had at least one prior systemic therapy or were not candidates for multiagent therapy.
  2. Sep 28, 2026Data cutoff for the updated first-line RMC-GI-102 cohort, in which 61 patients received daraxonrasib 200 mg daily plus gemcitabine and nab-paclitaxel.
  3. Nov 16, 2026The European Commission approved Rasonque as monotherapy for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, with or without an identified RAS tumor mutation.

Key terms

RAS
A family of small GTPase proteins that transmit signals inside cells and regulate growth and other behaviors.
KRAS
A gene encoding the K-Ras protein, part of the RAS/MAPK signaling pathway that controls cell growth and division.

Source: Wikipedia

Sources

Read the full story in the app Gistline — free on the App Store